Project Grant P01HL187164
Award Date 8/20/26
Completion Date 6/30/31
Dollars Obligated $3.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded $1.175 million to Icahn School of Medicine at Mount Sinai on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate hemogenic mesoderm heterogeneity, regulation, and function in the developing mammalian hematopoietic system. The research, led by Dr. Sturgeon, delineates the molecular and transcriptional mechanisms by which hemogenic mesoderm gives rise to embryonic hematopoietic programs. The work...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $453,834 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a tissue-selective modified mRNA delivery system for cardiac injury prevention and treatment. The recipient is developing CMSMRTS 143-122, a cardiomyocyte-selective modified mRNA system encapsulated in lipid nanoparticles for intravenous administration. The system targets acid ceramidase mRNA...
- The National Heart Lung and Blood Institute awarded Icahn School of Medicine at Mount Sinai $763,862 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the metabolic control of immune cell function in atherogenesis. The research examines the role of methylmalonic acid (MMA)—a byproduct of propionyl-CoA catabolism—in macrophage inflammatory processes that drive atherosclerotic cardiovascular disease. Preliminary data show that genetic deficiency of...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $1.669 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for data-consistent motion-correction reconstruction of PET/MR imaging targeting coronary atherosclerotic plaque activity. The research addresses motion artifacts that degrade spatial resolution and quantitative accuracy in coronary PET imaging, particularly for low-count tracers such as 68GA-DOTATATE....
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $850,669 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate place-based drivers of health in sickle cell disease pathogenesis. The project will identify and quantify mechanisms linking neighborhood and personal exposures—including crime-related stressors, unhealthy food access, temperature, airborne particulates, and housing conditions—to clinical...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $570,666 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a streamlined base editor reengineering platform that enhances gene editing specificity and selectivity for therapeutic applications. The recipient will establish an engineering platform to accelerate base editor development by integrating a naturally occurring...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded Icahn School of Medicine at Mount Sinai $1.71 million on June 22, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct genome-wide association studies identifying genetic variants that explain why some obese individuals remain metabolically healthy while some normal-weight individuals face elevated cardiometabolic risk. The recipient will use an integrative approach to discover genes and pathways that...
- The National Heart, Lung, and Blood Institute awarded the Trustees of Indiana University $516,592 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct integrative genomic analysis and develop high-dimensional risk prediction models for congenital heart defects using random field methods. The research leverages existing biospecimens and data from the National Birth Defect Prevention Studies, the Pediatric Cardiac Genomics Consortium, and the Trans-Omics for...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $124,688 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decode the gene regulatory network of mammalian cardiac maturation. The award funds a K99/R00 research project investigating the molecular mechanisms driving postnatal cardiac development. During the K99 phase, the recipient will characterize epigenomic changes in the mouse heart during...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the Icahn School of Medicine at Mount Sinai a $447,977 Project Grant effective September 1, 2025, through August 31, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). The Cardiovascular Science Training Program (CSTP) provides research training and mentorship to pre-doctoral and post-doctoral scientists pursuing independent careers in cardiovascular research. The program delivers...